Jazz Pharmaceuticals price target raised to $235 from $210 at Needham

5 days ago 2

TipRanks

Tue, January 13, 2026 astatine 6:43 AM CST 1 min read

Needham expert Ami Fadia raised the firm’s price target connected Jazz Pharmaceuticals (JAZZ) to $235 from $210 and keeps a Buy standing connected the shares. The steadfast cites the institution having presented the HERIZON-GEA-01 survey with further colour connected the subgroup analysis, noting that the wide information favored zani attraction arms crossed each subgroups with a longer process connected PFS for tislelizumab limb and somewhat higher efficacy successful TAP nether 1% implicit TAPat 1% oregon higher. A cardinal sentiment person connected the telephone besides noted that the payment demonstrated by zani is “practice-changing” and anticipates zanidatamab positive chemo tislelizumab volition rapidly regenerate the existent modular of care, the expert tells investors successful a probe note.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected JAZZ:

Disclaimer & DisclosureReport an Issue

BofA ups Jazz Pharmaceuticals terms target, says selloff ‘unwarranted’
Closing Bell Movers: AXT Inc. slips aft cutting Q4 gross guidance
Jazz Pharmaceuticals names Thomas Riga arsenic Chief Business Officer
Jazz Pharmaceuticals terms people raised to $225 from $205 astatine Morgan Stanley
Buy Rating connected Jazz Pharmaceuticals Driven by Zanidatamab’s Differentiated Efficacy and Clear Regulatory Path successful First-Line HER2+ GEA

Read Entire Article